drugset / Trial / NCT06336824
Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia
RandomizedParallel-groupOpen-labelTreatment
Summary
The Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus aureus Bacteraemia (EVOS) study is a multicentre, randomized, open-label, parallel group, phase 3, non-inferiority trial of early intravenous to oral antibiotic switch in comparison with standard intravenous antibiotic regime among patients with uncomplicated Staphylococcus aureus bacteraemia (SAB). The study is based on the hypothesis that an early switch from IV to oral antimicrobial therapy is non-inferior and safe compared to conventional minimum 14-day course of IV therapy in patients with low-risk uncomplicated SAB.
Timeline
- Start
- 2024-06-28
- Primary completion
- 2025-05
- Completion
- 2025-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CEPHALEXIN ANHYDROUS | Small molecule | 1 g | Oral |
| Comparator | Cefazolin | Small molecule | 2 g | Intravenous |
| Comparator | Ceftaroline | Other / unclassified | 600 mg | Intravenous |
| Subject | Clindamycin | Unknown | 600 mg | Oral |
| Subject | Linezolid | Other / unclassified | 600 mg | Oral |
| Comparator | Vancomycin | Other / unclassified | 15 mg/kg | Intravenous |
| Comparator | cloxacillin | Other / unclassified | 2 g | Intravenous |
| Subject | trimethoprim-sulfamethoxazole | Unknown | 10 mg/kg | Oral |